塞浦路斯的肌缩性侧面硬化症的遗传流行病学:基于人口的研究
Ellie Mitsi1,2,3, Christina Votsi1,3, Pantelitsa Koutsou1,3
1Neurogenetics Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Scientific reports
|December 27, 2024
概括
C9orf72 G4C2重复扩张是希腊塞浦路斯人群中肌缩侧面硬化症 (ALS) 的主要遗传原因. 这项研究确定了七个与ALS相关的基因的变异,推进了个性化医学的洞察力.
科学领域:
- 神经遗传学 神经遗传学
- 分子生物学分子生物学
- 人口遗传学 人口遗传学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种致命的神经退行性疾病,其特征是肌肉逐渐衰弱和缩.
- 遗传因素在ALS病因学中起着重要作用,已经确定了50多个致病或疾病修饰基因.
- 了解特定人口的遗传原因对于开发针对ALS的个性化医疗方法至关重要.
研究的目的:
- 在希腊塞浦路斯人群体中调查ALS的遗传基础.
- 确定与家族性 (fALS) 和零星 (sALS) 形式的ALS相关的常见和罕见遗传变异.
- 将遗传发现与潜在的治疗策略和个性化药物开发相关联.
主要方法:
- 在希腊-塞浦路斯队列中,从89名ALS患者 (21名fALS,68名sALS) 中收集了临床和遗传数据.
- 变异查专注于最常见的ALS相关基因.
- 使用下一代测序 (NGS) 和in silico预测工具来识别罕见变异并预测它们的功能影响.
主要成果:
- 在C9orf72基因中,致病性六核酸G4C2重复扩张是最常见的遗传原因,在22.47%的队列中被确定.
- 还检测到了另外六个与ALS相关的基因 (ALS2,TARDBP,FIG4,TBK1,GLT8D1和BICD2) 的变异.
- 该研究提供了该特定人群中ALS的综合遗传特征.
结论:
- C9orf72 G4C2重复扩张是希腊塞浦路斯人口中ALS的主要遗传驱动因素.
- 鉴定的遗传变异有助于了解ALS异质性的理解.
- 这些发现支持了针对人群的基因分析对于推进ALS诊断和个性化治疗策略的重要性.
相关概念视频
01:23Cystic Fibrosis: Pathogenesis
1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28